Market Overview

Medtronic Completes Enrollment in Landmark Study of IN.PACT Drug-Eluting Balloon in Peripheral Artery Disease

Related MDT
UPDATE: Credit Suisse Reiterates On Medtronic As Solid F2Q Showcases New Product Strength
#PreMarket Primer: Wednesday, November 19: Burst Of Cold Creates Chaos In New York
JPM Denies Report of Second Hack Attack (Fox Business)

Committed to researching treatments for peripheral artery disease, Medtronic, Inc. (NYSE: MDT) today announced that patient enrollment in a landmark study of its IN.PACT Amphirion drug-eluting balloon is complete, with initial results expected in 2013.

The largest randomized controlled trial of its kind, IN.PACT DEEP is designed to assess the safety and efficacy of the IN.PACT Amphirion drug-eluting balloon as a treatment for one of the most severe forms of peripheral artery disease -- critical limb ischemia that occurs below the knee.

Posted-In: News FDA

 

Related Articles (MDT)

Around the Web, We're Loving...

Get Benzinga's Newsletters